**CLAIMS**

1. Use of a LINC complex inhibitor in the manufacture of a medicament for preventing or treating fibrosis or a disease associated with fibrosis in a subject.

2. The use of claim 1, wherein the disease associated with fibrosis is skin, liver or lung fibrosis.

3. The use of claim 1 or 2, wherein the LINC complex inhibitor inhibits durotaxis or TGFβ activity in the subject.

4. The use of any one of claims 1 to 3, wherein the LINC complex inhibitor is a nucleic acid, polypeptide and/or small molecule.

5. The use of any one of claims 1 to 4, wherein the LINC complex inhibitor is an inhibitor of a gene encoding SUN2, SUN1, Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4 or KASH5, optionally wherein the LINC complex inhibitor is an inhibitor of a gene encoding SUN2.

6. The use of any one of claims 1 to 5, wherein the LINC complex inhibitor is an inhibitory nucleic acid molecule or site-specific nuclease (SSN) system that is capable of disrupting a gene encoding a LINC complex protein.

7. The use of claim 6, wherein the LINC complex inhibitor is an inhibitory nucleic acid molecule, wherein the inhibitory nucleic acid molecule is an siRNA, shRNA, ASO or miRNA.

8. The use of claim 6, wherein the LINC complex inhibitor is a site-specific nuclease (SSN) system, wherein the SSN system is a CRISPR-Cas system, optionally wherein the CRISPR-Cas system is a CRISPR-Cas9 system.

9. The use of claim 1 or 2, wherein the LINC complex inhibitor is a polypeptide derived from a LINC complex protein, optionally wherein the LINC complex inhibitor is a dominant negative SUN1 polypeptide.

10. The use of claim 9, wherein the LINC complex inhibitor is a polypeptide derived from SUN1 and/or SUN2 or is a polypeptide derived from Nesprin-1, Nesprin-2, Nesprin-3, Nesprin-4 and/or KASH5.

11. Use of a LINC complex inhibitor in the manufacture of a medicament for inhibiting or preventing metastasis of a cancer, or for treating a metastatic cancer, in a subject.

12. Use of a LINC complex inhibitor in the manufacture of a medicament for treating or preventing a disease associated with inflammation in a subject.

13. Use of a LINC complex inhibitor in the manufacture of a medicament for promoting wound healing or tissue regeneration, or for treating a wound, in a subject.

14. Use of a LINC complex inhibitor in the manufacture of a medicament for inhibiting durotaxis in a cell.

15. The use according to claim 14, wherein the cell is a hepatocyte, a myofibroblast, an immune cell or a cancer cell.